XML 45 R37.htm IDEA: XBRL DOCUMENT
v3.25.3

Net Income (Loss) Per Share (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Summary of Weighted Average Number of Shares of Common Stock Outstanding |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Basic net income (loss) per share: |  |  |  |  |  |  |  |  |  |  |  |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 554,242 |  |  | $ | (62,310,678 | ) |  | $ | (34,899,390 | ) |  | $ | (65,575,171 | )
Net income (loss) attributable to common stockholders, basic and diluted |  | $ | 554,242 |  |  | $ | (62,310,678 | ) |  | $ | (34,899,390 | ) |  | $ | (65,575,171 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average shares used to compute net income (loss) per share, basic and diluted |  |  | 46,911,561 |  |  |  | 5,836,882 |  |  |  | 39,781,781 |  |  |  | 5,836,882 |
Net income (loss) per share attributable to common stockholders, basic and diluted |  | $ | 0.01 |  |  | $ | (10.68 | ) |  | $ | (0.88 | ) |  | $ | (11.23 | )
Summary of Calculation of Diluted Net income (Loss) Per Share | The following potential Common Stock were excluded from the calculation of diluted net income (loss) per share because their effect would have been anti-dilutive for the periods presented:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Convertible preferred stock |  | - |  |  |  | 10,204,880 |  |  |  | - |  |  |  | 10,204,880 |
Unvested restricted stock units (1) |  |  | 3,725,058 |  |  |  | 2,099,441 |  |  |  | 3,725,058 |  |  |  | 2,099,441 |
SAFEs (2) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Convertible notes (3) |  |  | 5,924,582 |  |  |  | - |  |  |  | 5,924,582 |  |  |  | - |
Investor warrants (4) |  |  | 15,099,378 |  |  |  | - |  |  |  | 15,099,378 |  |  |  | - |
Total anti-dilutive securities |  |  | 24,749,018 |  |  |  | 12,304,321 |  |  |  | 24,749,018 |  |  |  | 12,304,321 |
(1) Potentially dilutive securities attributable to outstanding unvested restricted stock units are excluded from the calculation of diluted net income per share when the combined exercise price and average unamortized fair value are greater than the average market price of the Company's Common Stock, and, therefore, their inclusion would be anti-dilutive. (2) The SAFEs were not included for purposes of calculating the number of diluted shares outstanding for the three and nine months ended September 30, 2025 as the SAFEs were converted to Common Stock as of the Merger. The SAFEs were not included for purposes of calculating the number of diluted shares outstanding for the three and nine months ended September 30, 2024 as the number of dilutive shares would be based on a conversion ratio associated with the pricing of the future financing or liquidation event, which was not determinable as of September 30, 2024. (3) The June 2025 Amended Note contains a conversion feature that allows the investor the option to convert the June 2025 Amended Note in exchange f or 2,222,222 shares of Common Stock. The March 2025 Investor Note contains a conversion feature that allows the investor the option to convert in exchange for 3,702,360 shares of Common Stock. The effect of the incremental Common Stock issuable upon a conversion of these notes would be anti-dilutive based on Fold's average share price for the three and nine months ended September 30, 2025 and are therefore excluded from the income (loss) per share calculation. (4) As of September 30, 2025, Fold had (1) 12,434,658 public warrants related to legacy FTAC Emerald at an exercise price of $11.50; (2) 869,565 Series A and 869,565 Series C Warrants outstanding related to the June 2025 Amended Investor Note, at an exercise price of $12.50 and $9.00, respectively; and (3) 925,590 March 2025 Warrants outstanding related to the March 2025 Investor Note at an exercise price of $15.00. These warrants are considered anti-dilutive based on Fold's average share price for the three and nine months ended September 30, 2025 and are therefore excluded from the income (loss) per share calculation.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration